{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:39:05Z","timestamp":1792809545875,"version":"4.5.0"},"reference-count":50,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with chemotherapy\u2010 and androgen receptor pathway inhibitor (ARPI)\u2010na\u00efve metastatic castration\u2010resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic health records (EHRs) is needed to confirm this finding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This EHR\u2010based analysis (2014\u20132023) of the Flatiron Health database included patients with chemotherapy\u2010 and ARPI\u2010na\u00efve mCRPC who initiated first\u2010line ARPI (abiraterone or enzalutamide). OS, treatment duration, and time to subsequent therapy were assessed. A subgroup analysis evaluated patients who received first\u2010line ARPI only with no subsequent treatments. Kaplan\u2013Meier method and Cox proportional hazards models evaluated time\u2010to\u2010event outcomes. Stabilized inverse probability treatment weighting (sIPTW) adjusted for baseline differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 2731 patients, 1316 received first\u2010line abiraterone and 1415 enzalutamide (median follow\u2010up: 21.8 and 23.2\u2009months, respectively). sIPTW\u2010adjusted median OS (24.6 vs. 25.8\u2009months; hazard ratio [HR] 1.13; 95% confidence interval [CI], 1.03\u20131.23), treatment duration (7.9 vs. 9.5\u2009months; HR 1.21; 95% CI, 1.11\u20131.31), and time to subsequent therapy (14.7 vs. 17.9\u2009months; HR 1.20; 95% CI, 1.08\u20131.32) were shorter with abiraterone versus enzalutamide. Among the 40% with no subsequent treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091102), sIPTW\u2010adjusted median OS (14.0 vs. 17.7\u2009months; HR 1.32; 95% CI, 1.14\u20131.53), and treatment duration (7.5 vs. 10.6\u2009months; HR 1.30; 95% CI, 1.12\u20131.50) were also shorter with abiraterone versus enzalutamide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using more detailed data abstraction, these results confirm prior claims\u2010based analyses showing that despite early use of subsequent therapy, first\u2010line abiraterone is associated with shorter OS versus enzalutamide in ARPI\u2010 and chemotherapy\u2010na\u00efve mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinical Trial ID: NCT05968599<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72356","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:39:40Z","timestamp":1791866380000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy\u2010Na\u00efve Metastatic Castration\u2010Resistant Prostate Cancer From the Flatiron Electronic Health Records Database"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-7203","authenticated-orcid":false,"given":"Daniel J.","family":"George","sequence":"first","affiliation":[{"name":"Duke Cancer Institute  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina I.","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Touya","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc.  Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Thompson","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Assayag","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kountouris","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Siu","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  Los Angeles California USA"},{"name":"Durham VA Medical Center  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.08.018"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.061"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)71205\u20107"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.012"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8560827"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23309"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010024\u201000816\u20100"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010021\u201000318\u20103"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010022\u201000588\u20105"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.102148"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28444"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1491314"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa190"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.822375"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.669236"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391\u2010023\u201000725\u20108"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42093"},{"key":"e_1_2_12_21_1","unstructured":"Flatiron Health \u201cDatabase Characterization Guide \u201daccessed February 12 2026 https:\/\/flatiron.com\/database\u2010characterization."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.12.019"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(96)00075\u2010x"},{"key":"e_1_2_12_24_1","unstructured":"P.Cornford D.Tilki R. C. N.van denBergh et\u00a0al. \u201cEAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer \u201dpresented at EAU Guidelines Edn Presented at the EAU Annual Congress Paris April 2024 Arnhem the Netherlands https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full\u2010guideline\/EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010ISUP\u2010SIOG\u2010Guidelines\u2010on\u2010Prostate\u2010Cancer\u20102024_2024\u201004\u201009\u2010132035_ypmy.pdf."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00155"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.198"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010025\u201001148\u20102"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.64"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010026\u201001230\u20103"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30688\u20106"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201024\u201001045"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.07.006"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.28"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100261"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201024\u201000690"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.07.002"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.104"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102386"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.74"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102170"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad046"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2470616"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002073\u2010w"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.049"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102574"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153773"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/1008\u2010682x.178483"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24923"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010025\u201003132\u20108"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:04Z","timestamp":1792807744000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cam4.72356"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72356","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72356"}}